N4P.L

N4 Pharma Plc
N4 Pharma PLC - Result of AGM
23rd May 2024, 11:19
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6939P
N4 Pharma PLC
23 May 2024
 

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Result of Annual General Meeting

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.

 

 

Resolution

For

For%

Against

Against%

Total

Witheld votes*

Ordinary Resolution 1

To receive the annual report and audited accounts for the year

ended 31 December 2023

20,612,844

99.93%

13,980

0.07%

20,626,824

296,841

Ordinary Resolution 2

To re-elect Nigel Theobald as a Director of the Company

20,605,744

99.32%

141,080

0.68%

20,746,824

176,841

Ordinary Resolution 3

To re-elect David Templeton as a Director of the Company

20,605,744

99.32%

141,080

0.68%

20,746,824

176,841

Ordinary Resolution 4

To re-appoint Saffery Champness LLP as the Companyʼs auditor

and to authorise the Directors to determine their remuneration

20,605,644

99.32%

140,980

0.68%

20,746,624

177,041

Ordinary Resolution 5

To authorise the Directors to allot shares

20,559,085

99.10%

187,539

0.90%

20,746,624

177,041

Special Resolution 6

To disapply pre-emption rights

20,506,310

99.00%

207,439

1.00%

20,713,749

209,916

 

*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

 

For more information please contact:

 

N4 Pharma plc

Nigel Theobald, CEO

Luke Cairns, Executive Director

investors.n4pharma.com

 

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

InvestorHub

Engage with us directly at N4 Pharma Investor Hub

Sign up at investors.n4pharma.com

 

https://investors.n4pharma.com/link/Ky0AZe

 

Turner Pope Investments (TPI) Limited

Joint Broker

Andy Thacker

James Pope

Tel: +44(0)20 3657 0050

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBBGDUIBDDGSX]]>
TwitterFacebookLinkedIn